INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106701, 'Glipizide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106824/', '', 'Simvastatin, Guar gum, Rosuvastatin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106702, 'Glyburide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106825/', '', 'Simvastatin, Guar gum, Rosuvastatin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106703, 'Hydromorphone', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106826/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106704, 'Insulin human', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106827/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106705, 'Insulin aspart (aspart)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106828/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106706, 'Insulin aspart (aspart protamine)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106829/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106707, 'Insulin degludec', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106830/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106708, 'Insulin detemir', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106831/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106709, 'Insulin glargine', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106832/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106710, 'Insulin glulisine', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106833/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106711, 'Insulin human (inhalation, rapid acting)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106834/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106712, 'Insulin human (isophane)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106835/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106713, 'Insulin lispro', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106836/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106714, 'Insulin lispro (protamine)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106837/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106715, 'Insulin human (regular)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106838/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106716, 'Insulin human (zinc)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106839/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106717, 'Insulin human (zinc extended)', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106840/', '', '', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106718, 'Pegvisomant', 'Levacetylmethadol', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106841/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Tetracosactide, Mecasermin rinfabate', 'Diamorphine, Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106719, 'Pegvisomant', 'Levorphanol', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106842/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106720, 'Pegvisomant', 'Linagliptin', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106843/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106721, 'Pegvisomant', 'Liraglutide', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106844/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106722, 'Pegvisomant', 'Lixisenatide', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106845/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106723, 'Pegvisomant', 'Meperidine', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106846/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106724, 'Pegvisomant', 'Miglitol', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106847/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106725, 'Pegvisomant', 'Morphine (liposomal)', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106848/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106726, 'Pegvisomant', 'Nalbuphine', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106849/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106727, 'Pegvisomant', 'Nateglinide', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106850/', '', 'Simvastatin, Guar gum, Rosuvastatin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106728, 'Pegvisomant', 'Oliceridine', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106851/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106729, 'Pegvisomant', 'Opium', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106852/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106730, 'Pegvisomant', 'Oxymorphone', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106853/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106731, 'Pentazocine', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106854/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106732, 'Pramlintide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106855/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106733, 'Dextropropoxyphene', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106856/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106734, 'Remifentanil', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106857/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106735, 'Repaglinide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106858/', '', 'Simvastatin, Guar gum, Rosuvastatin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106736, 'Rosiglitazone', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106859/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106737, 'Saxagliptin', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106860/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106738, 'Semaglutide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106861/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106739, 'Sitagliptin', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106862/', '', 'Mecasermin, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106740, 'Sufentanil', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106863/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106741, 'Tapentadol', 'Pegvisomant', 'Moderate', 'In clinical trials, patients on opioids often required higher serum pegvisomant concentrations to achieve appropriate IGF-I (insulin-like growth factor-I) suppression compared with patients not receiving opioids.', 'DDInter', 'Clinicians should be aware of this potential interaction and adjust the dosage of pegvisomant appropriately in patients treated with opioids.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106864/', '', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Somatrem, Somatotropin, Tetracosactide, Mecasermin rinfabate, Somapacitan', 'Naltrexone, Acetaminophen, Ibuprofen, Celecoxib, Acetylsalicylic acid, Naloxone', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106742, 'Tolazamide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106865/', '', 'Simvastatin, Guar gum, Rosuvastatin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106743, 'Tolbutamide', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106866/', '', 'Sorbitol, Caffeine, Edrophonium, Indocyanine green, Inulin, Hexaminolevulinate, Secretin human, Galactose, Corticorelin, Macimorelin, Methacholine, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106744, 'Troglitazone', 'Pegvisomant', 'Moderate', 'Treatment with pegvisomant may increase glucose tolerance in some diabetic patients, potentially reducing their requirements for insulin and other antidiabetic agents. The mechanism is pegvisomant antagonism of endogenous growth hormone, the latter of which normally decreases insulin sensitivity and opposes the effects of insulin on carbohydrate metabolism. However, clinically relevant hypoglycemia was not observed in diabetic patients who were treated with pegvisomant in premarketing trials.', 'DDInter', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary. Likewise, patients may be at risk for hyperglycemia when pegvisomant is withdrawn from their therapeutic regimen.', 'Synergism', 'Close clinical monitoring of glycemic control is recommended when pegvisomant is used in patients receiving insulin or other antidiabetic agents, and the dosages of these agents adjusted as necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106867/', '', 'Mecasermin, Somatrem, Mecasermin rinfabate', 'Simvastatin, Guar gum, Rosuvastatin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106745, 'Pembrolizumab', 'Lenalidomide', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106868/', '', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More', 'Pertuzumab, Cetuximab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Amivantamab, Ramucirumab, Rituximab, Sacituzumab govitecan, Trastuzumab deruxtecan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106746, 'Pembrolizumab', 'Methylprednisolone', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', 'DDInter', 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'The manufacturers'' product labeling should be consulted for specific recommendations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106869/', '', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106747, 'Pomalidomide', 'Pembrolizumab', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106870/', '', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More', 'Pertuzumab, Cetuximab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Amivantamab, Ramucirumab, Rituximab, Sacituzumab govitecan, Trastuzumab deruxtecan, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106748, 'Prednisolone', 'Pembrolizumab', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', 'DDInter', 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'The manufacturers'' product labeling should be consulted for specific recommendations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106871/', '', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fludrocortisone, Indomethacin, More', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106749, 'Prednisone', 'Pembrolizumab', 'Moderate', 'INTERVAL: Corticosteroids may affect the pharmacodynamic effects and efficacy of immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1) or programmed death ligand-1 inhibitors (PD-L1). The mechanism of this interaction is unknown; however, it has been theorized that the immunosuppressive properties of corticosteroids and the potential effect on T-cell function may decrease the efficacy of ICIs.', 'DDInter', 'The manufacturers'' product labeling should be consulted for specific recommendations. If clinically possible, the use of systemic corticosteroids should be avoided at the time of or within 30 days of starting therapy with an ICI, e.g., durvalumab, nivolumab, pembrolizumab, ipilimumab, cemiplimab, or atezolizumab. Corticosteroids may be used for the treatment of immune-mediated reactions after starting an ICI. Some manufacturers advise that corticosteroids may be used as premedication, when the ICI is used in combination with chemotherapy, as antiemetic prophylaxis, and/or to alleviate chemotherapy-related adverse effects.', 'Antagonism', 'The manufacturers'' product labeling should be consulted for specific recommendations.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106872/', '', 'Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine, Fludrocortisone', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Amivantamab, Rituximab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106750, 'Thalidomide', 'Pembrolizumab', 'Major', 'Coadministration of thalidomide or its analogs with a programmed death receptor-1 (PD-1) or programmed death ligand-1 (PD-L1) blocking antibody may increase the risk of mortality in patients with multiple myeloma. The mechanism has not been established.', 'DDInter', 'Concomitant use of a PD-1 or PD-L1 blocking antibody with thalidomide or a thalidomide analog plus dexamethasone in the treatment of multiple myeloma is not recommended outside of controlled clinical trials.', 'Others', '', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106873/', '', 'Golimumab, Cyclosporine, Antithymocyte immunoglobulin (rabbit), Ravulizumab, Diroximel fumarate, Methotrexate, Inebilizumab, Belumosudil, Ozanimod, Emapalumab, Natalizumab, More', 'Pertuzumab, Trastuzumab deruxtecan, Olaratumab, Panitumumab, Tafasitamab, Obinutuzumab, Amivantamab, Ramucirumab, Belantamab mafodotin, Mogamulizumab, Blinatumomab, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106751, 'Talimogene laherparepvec', 'Penciclovir (topical)', 'Moderate', 'Antiherpetic antiviral agents may interfere with the therapeutic effects of talimogene laherparepvec, which is a live, attenuated herpes simplex virus.', 'DDInter', 'Because talimogene laherparepvec is sensitive to antiviral agents such as acyclovir, the risks and benefits of talimogene laherparepvec should be considered before administering antiviral agents to manage herpetic infection.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106874/', '', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106752, 'Anisindione', 'Benzylpenicillin', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106875/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106753, 'Dicoumarol', 'Benzylpenicillin', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106876/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106754, 'Indium In-111 oxyquinoline', 'Benzylpenicillin', 'Moderate', 'Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.', 'DDInter', 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106877/', '', 'Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106755, 'Benzylpenicillin', 'Oxytetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106878/', '', 'Tigecycline, Omadacycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Ofloxacin, Netilmicin, Polymyxin B, More', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Polymyxin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106756, 'Benzylpenicillin', 'Pemetrexed', 'Moderate', 'Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.', 'Excretion', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106879/', '', 'Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More', 'Tazobactam, Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Sulfisoxazole, Azithromycin, Erythromycin, Chlorhexidine, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106757, 'Benzylpenicillin', 'Probenecid', 'Minor', 'Probenecid may increase the plasma concentrations and half-lives of penicillins. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of penicillins. While this interaction is often exploited to enhance the antibacterial effect of penicillins, toxicity may occur and should be considered if high penicillin dosages are administered intravenously.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106880/', '', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More', 'Sulbactam, Rifamycin, Kanamycin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Tobramycin, Gentamicin, Erythromycin, Neomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106758, 'Benzylpenicillin', 'Sarecycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106881/', '', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', 'Tigecycline, Omadacycline, Eravacycline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106759, 'Iodide I-131', 'Benzylpenicillin', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106882/', '', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', 'Ibritumomab tiuxetan, Tositumomab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106760, 'Benzylpenicillin', 'Tetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106883/', '', 'Rifamycin, Miconazole, Polymyxin B, Chlorhexidine, Neomycin, Ofloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, Metronidazole, Vonoprazan, More', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106761, 'Benzylpenicillin', 'Troleandomycin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106884/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, More', 'Telithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106762, 'Typhoid vaccine (live)', 'Benzylpenicillin', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', 'DDInter', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106885/', '', 'Procaine benzylpenicillin, Sulbactam, Tazobactam, Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106763, 'Warfarin', 'Benzylpenicillin', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106886/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Tazobactam, Sulbactam, Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Trifluridine, Amikacin, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106764, 'Anisindione', 'Benzylpenicillin (potassium)', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106887/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106765, 'Demeclocycline', 'Benzylpenicillin (potassium)', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106888/', '', 'Tigecycline, Omadacycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Rifaximin, Gentamicin, Amikacin, Neomycin', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106766, 'Dicoumarol', 'Benzylpenicillin (potassium)', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106889/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Ganciclovir, Acyclovir, Rifamycin, Kanamycin, Netilmicin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106767, 'Entecavir', 'Benzylpenicillin (potassium)', 'Moderate', 'Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106890/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', 'Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Chloramphenicol, Sulfisoxazole, Azithromycin, Erythromycin, Chlorhexidine, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106768, 'Heparin', 'Benzylpenicillin (potassium)', 'Minor', 'Case reports have suggested that intravenous penicillins may intensify the effect of heparin by inhibition of platelet aggregation; however, causality has not been clearly determined. Patients should be monitored for bleeding problems. Protamine sulfate may be useful for clinically important bleeding.', 'DDInter', '-', 'Synergism', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106891/', '', 'Sulbactam, Carbenicillin, Bacampicillin, Tazobactam, Cloxacillin, Benzylpenicillin, Procaine benzylpenicillin, Rifamycin, Kanamycin, Oxytetracycline, Netilmicin, More', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106769, 'Indium In-111 oxyquinoline', 'Benzylpenicillin (potassium)', 'Moderate', 'Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.', 'DDInter', 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106892/', '', 'Tazobactam, Sulbactam, Ganciclovir, Acyclovir, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106770, 'Benzylpenicillin (potassium)', 'Mycophenolate mofetil', 'Moderate', 'Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.', 'DDInter', 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106893/', '', 'Tazobactam, Sulbactam, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106771, 'Benzylpenicillin (potassium)', 'Mycophenolic acid', 'Moderate', 'Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.', 'DDInter', 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106894/', '', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, More', 'Tazobactam, Sulbactam, Rifamycin, Famciclovir, Trifluridine, Chlorhexidine, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106772, 'Benzylpenicillin (potassium)', 'Oxytetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106895/', '', 'Tigecycline, Omadacycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Ofloxacin, Acyclovir, Netilmicin, More', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Polymyxin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106773, 'Benzylpenicillin (potassium)', 'Pemetrexed', 'Moderate', 'Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.', 'Excretion', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106896/', '', 'Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Fludarabine, More', 'Tazobactam, Tetracycline, Rifamycin, Oxytetracycline, Sulfamethizole, Trifluridine, Sulfisoxazole, Azithromycin, Erythromycin, Chlorhexidine, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106774, 'Benzylpenicillin (potassium)', 'Probenecid', 'Minor', 'Probenecid may increase the plasma concentrations and half-lives of penicillins. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of penicillins. While this interaction is often exploited to enhance the antibacterial effect of penicillins, toxicity may occur and should be considered if high penicillin dosages are administered intravenously.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106897/', '', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Allopurinol, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, More', 'Sulbactam, Rifamycin, Kanamycin, Azithromycin, Netilmicin, Polymyxin B, Trifluridine, Tobramycin, Gentamicin, Erythromycin, Neomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106775, 'Benzylpenicillin (potassium)', 'Sarecycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106898/', '', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', 'Tigecycline, Omadacycline, Eravacycline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106776, 'Iodide I-123', 'Benzylpenicillin (potassium)', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106899/', '', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106777, 'Iodide I-131', 'Benzylpenicillin (potassium)', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106900/', '', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, Ofloxacin, Acyclovir, Netilmicin, Ciprofloxacin, More', 'Ibritumomab tiuxetan, Tositumomab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106778, 'Benzylpenicillin (potassium)', 'Tetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106901/', '', 'Rifamycin, Miconazole, Polymyxin B, Ciprofloxacin, Gentamicin, Chlorhexidine, Neomycin, Ofloxacin, Tinidazole, Dexlansoprazole, Rabeprazole, More', 'Tazobactam, Sulbactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Netilmicin, Polymyxin B, Famciclovir, Trifluridine, Tobramycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106779, 'Benzylpenicillin (potassium)', 'Troleandomycin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106902/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Azithromycin, More', 'Dirithromycin, Telithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106780, 'Benzylpenicillin (potassium)', 'Typhoid vaccine (live)', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', 'DDInter', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106903/', '', 'Procaine benzylpenicillin, Sulbactam, Tazobactam, Ganciclovir, Acyclovir, Famciclovir, Chlorhexidine, Povidone-iodine', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106781, 'Warfarin', 'Benzylpenicillin (potassium)', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106904/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, More', 'Tazobactam, Sulbactam, Ganciclovir, Rifamycin, Kanamycin, Netilmicin, Polymyxin B, Trifluridine, Amikacin, Povidone-iodine', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106782, 'Anisindione', 'Phenoxymethylpenicillin', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106905/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106783, 'Bifidobacterium longum infantis', 'Phenoxymethylpenicillin', 'Moderate', 'INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106906/', '', 'Sulbactam, Piperacillin, Meticillin, Carbenicillin, Ticarcillin, Mezlocillin, Tazobactam, Nafcillin, Benzylpenicillin, Procaine benzylpenicillin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106784, 'Demeclocycline', 'Phenoxymethylpenicillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106907/', '', 'Tazobactam, Sulbactam', 'Tigecycline, Omadacycline, Eravacycline, Mupirocin, Rifamycin, Bacitracin, Chloramphenicol, Rifaximin, Gentamicin, Amikacin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106785, 'Dicoumarol', 'Phenoxymethylpenicillin', 'Moderate', 'Penicillins may occasionally potentiate the risk of bleeding in patients treated with oral anticoagulants. The exact mechanism of interaction is unknown but may involve penicillin inhibition of platelet aggregation.', 'DDInter', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment. The INR should be checked frequently and anticoagulant dosage adjusted accordingly, particularly following initiation or discontinuation of penicillin therapy in patients who are stabilized on their anticoagulant regimen. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Synergism', 'Caution is recommended if a penicillin is prescribed during oral anticoagulant therapy, especially in the elderly and patients with uremia or hepatic impairment.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106908/', '', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106786, 'Entecavir', 'Phenoxymethylpenicillin', 'Moderate', 'Coadministration of entecavir with another drug that is also eliminated by active tubular secretion may result in increased plasma concentrations of one or both drugs due to competitive inhibition of transporters in the renal tubules. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving entecavir with another drug that undergoes active tubular secretion should be monitored for excessive pharmacologic effects of both drugs, and the dosages adjusted as necessary.', 'Excretion', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106909/', '', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Maraviroc, Amprenavir, Simeprevir, Valaciclovir, Zanamivir, Cabotegravir, Lenacapavir, More', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106787, 'Indium In-111 oxyquinoline', 'Phenoxymethylpenicillin', 'Moderate', 'Certain medications may decrease chemotaxis and cause false-negative results with Indium In-111-labeled leukocyte studies.', 'DDInter', 'Clinicians should be aware of possible diagnostic interference in patients who are on long-term antibiotic treatment, corticosteroids, interleukin-2, parenteral nutrition, or high doses or supratherapeutic concentrations of lidocaine or procainamide.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106910/', '', 'Tazobactam, Sulbactam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106788, 'Phenoxymethylpenicillin', 'Lactobacillus acidophilus', 'Moderate', 'INTERVAL: Coadministration of oral probiotic preparations with oral antibiotics may reduce the efficacy of the probiotic. It has been theorized that concomitant antibiotics may kill the live organisms found in lactobacillus-, bacillus coagulans-, and bifidobacteria-containing oral probiotic preparations. However, the clinical significance of the interaction has not been established.', 'DDInter', 'Although data are limited, it may be prudent to advise patients to take oral probiotics at least 1 to 2 hours before or after an oral antibiotic.', 'Others', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106911/', '', 'Sulbactam, Piperacillin, Meticillin, Carbenicillin, Ticarcillin, Mezlocillin, Tazobactam, Nafcillin, Benzylpenicillin, Procaine benzylpenicillin', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106789, 'Phenoxymethylpenicillin', 'Mycophenolate mofetil', 'Moderate', 'Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.', 'DDInter', 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106912/', '', 'Tazobactam, Sulbactam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106790, 'Phenoxymethylpenicillin', 'Mycophenolic acid', 'Moderate', 'Theoretically, drugs that alter the gastrointestinal flora (e.g., antibiotics) may reduce the oral bioavailability of mycophenolic acid products. Some investigators believe that antimicrobials may interfere with the enterohepatic recirculation of mycophenolic acid by decreasing bacterial hydrolytic enzymes in the gastrointestinal tract that are responsible for regenerating mycophenolic acid from its glucuronide metabolite following first-pass metabolism.', 'DDInter', 'Close clinical and laboratory monitoring for evidence of diminished immunosuppressive effect of mycophenolic acid is recommended during concomitant therapy with anti-infective agents.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106913/', '', 'Tazobactam, Sulbactam', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Tacrolimus, Abatacept, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106791, 'Phenoxymethylpenicillin', 'Neomycin', 'Moderate', 'Limited data suggest that concomitant administration of oral neomycin with oral penicillin may reduce serum concentrations of penicillin. The proposed mechanism is neomycin-induced malabsorption. The clinical significance is unknown.', 'DDInter', 'It may be advisable to monitor patients for reduced penicillin efficacy, consider a different oral antibiotic, or consider administering parenteral penicillin.', 'Absorption', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106914/', '', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Rifamycin, Kanamycin, Amphotericin B, Miconazole, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Fidaxomicin, Rifaximin, Paromomycin, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106792, 'Phenoxymethylpenicillin', 'Oxytetracycline', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106915/', '', 'Tazobactam, Sulbactam', 'Tigecycline, Omadacycline, Eravacycline, Gatifloxacin, Rifamycin, Kanamycin, Lomefloxacin, Ampicillin, Ofloxacin, Netilmicin, Polymyxin B, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106793, 'Phenoxymethylpenicillin', 'Pemetrexed', 'Moderate', 'Coadministration with drugs that are eliminated by active tubular secretion may delay and/or decrease the clearance of pemetrexed. The mechanism is competitive inhibition of the renal excretion of pemetrexed, which is primarily eliminated unchanged via glomerular filtration and active tubular secretion. Drugs (and/or their metabolites) that are thought to undergo active tubular secretion include acyclovir, allopurinol, aminosalicylic acid, cidofovir, cimetidine, creatine, dyphylline, famciclovir, famotidine, flecainide, ganciclovir, levetiracetam, metformin, methotrexate, midodrine, mycophenolic acid, oseltamivir, pralatrexate, probenecid, procainamide, quinidine, ranitidine, tenofovir, triamterene, trimethoprim, valacyclovir, valganciclovir, zalcitabine, zidovudine, and many of the beta-lactam and quinolone antibiotics.', 'DDInter', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary. The potential for increased toxicity of pemetrexed such as bone marrow suppression should be considered. Renal function should be closely monitored during therapy.', 'Excretion', 'Patients receiving pemetrexed in combination with other drugs that undergo active tubular secretion should be monitored for excessive pharmacologic effects of one or both drugs, and the dosages of the drugs adjusted if necessary.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106916/', '', 'Tazobactam', 'Fluorouracil, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Nelarabine, Cytarabine, Pralatrexate, Decitabine, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106794, 'Probenecid', 'Phenoxymethylpenicillin', 'Minor', 'Probenecid may increase the plasma concentrations and half-lives of penicillins. The mechanism is competitive inhibition by probenecid of the renal tubular secretion of penicillins. While this interaction is often exploited to enhance the antibacterial effect of penicillins, toxicity may occur and should be considered if high penicillin dosages are administered intravenously.', 'DDInter', '-', 'Excretion', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106917/', '', 'Sulbactam', 'Lesinurad, Febuxostat, Pegloticase, Colchicine, Sulfinpyrazone, Rasburicase, Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106795, 'Sarecycline', 'Phenoxymethylpenicillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106918/', '', 'Tazobactam, Sulbactam', 'Tigecycline, Omadacycline, Eravacycline', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106796, 'Iodide I-123', 'Phenoxymethylpenicillin', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106919/', '', 'Tazobactam, Sulbactam', '', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106797, 'Iodide I-131', 'Phenoxymethylpenicillin', 'Moderate', 'INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.', 'DDInter', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.', 'Others', 'Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward.', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106920/', '', 'Tazobactam, Sulbactam', 'Ibritumomab tiuxetan, Tositumomab', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106798, 'Tetracycline', 'Phenoxymethylpenicillin', 'Moderate', 'Tetracyclines may reduce the effect of penicillins by inhibiting cellular protein synthesis which is necessary for cell wall synthesis inhibition by penicillins. Antagonism is more likely when low doses of either agent are administered. Therapeutic failure may result.', 'DDInter', 'This combination should be avoided if possible.', 'Antagonism', '', 'Moderate', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106921/', '', 'Tazobactam, Sulbactam', 'Rifamycin, Miconazole, Polymyxin B, Chloramphenicol, Gentamicin, Chlorhexidine, Ofloxacin, Tinidazole, Pantoprazole, Levofloxacin, Dexlansoprazole, More', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106799, 'Troleandomycin', 'Phenoxymethylpenicillin', 'Minor', 'Although some in vitro data indicate synergism between macrolide antibiotics and penicillins, other in vitro data indicate antagonism. When these drugs are given together, neither has predictable therapeutic efficacy. Data are available for erythromycin, although theoretically this interaction could occur with any macrolide. Except for monitoring of the effectiveness of antibiotic therapy, no special precautions appear to be necessary.', 'DDInter', '-', 'Others', '', 'Minor', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106922/', '', 'Sulbactam, Meticillin, Bacampicillin, Mezlocillin, Cloxacillin, Tazobactam', 'Dirithromycin, Telithromycin, Lincomycin, Clindamycin', 1767369485);
INSERT OR IGNORE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, source, management_text, mechanism_text, recommendation, risk_level, type, metabolism_info, source_url, reference_text, alternatives_a, alternatives_b, updated_at) VALUES (106800, 'Typhoid vaccine (live)', 'Phenoxymethylpenicillin', 'Major', 'INTERVAL: The use of live, attenuated oral typhoid vaccine with antibacterial sulfonamides or other antibiotics may result in a diminished immunologic response to the vaccine. Some antibiotics may be active against the vaccine strain of Salmonella typhi (Ty21a), thereby preventing a sufficient degree of multiplication to occur in order to induce a protective immune response.', 'DDInter', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics. A longer interval should be considered following treatment with long-acting antibiotics (e.g., azithromycin). If malaria prophylaxis is needed, the same 3-day interval at the minimum should be observed between antimalarials and the vaccine. However, chloroquine, mefloquine, and pyrimethamine-sulfadoxine may be given concomitantly with the vaccine. Alternatively, parenteral typhoid vaccine (typhoid Vi polysaccharide vaccine) may be considered if coadministration with antibacterial agents is required.', 'Others', 'Live, attenuated oral typhoid vaccine should not be administered during and for at least 3 days before and after treatment with antibacterial sulfonamides or other antibiotics.', 'Major', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/106923/', '', 'Procaine benzylpenicillin, Sulbactam, Tazobactam', '', 1767369485);
